Alzheimer's Therapeutic Research Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: San Diego CA United States (2015)

Organization Overview

First Clinical Trial
2015
NCT01767909
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Alzheimer's Therapeutic Research Institute

Active Ingredients

Drugs in Phase 3 Trials (2)

insulin human (humulin) (1 trial)

solanezumab (1 trial)

Drugs in Phase 2 Trials (4)

cannabidiol (Epidiolex) (1 trial)

nicotine (nicorette) (1 trial)

saracatinib (1 trial)

tetrahydrocannabinol (1 trial)

Drugs in Phase 1 Trials (1)

flortaucipir (Tauvid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Cognition Disorders (Phase 3)

Cognitive Dysfunction (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 7